Estradiol - Acrux

Drug Profile

Estradiol - Acrux

Alternative Names: Ellavie; Estradiol MDTS®; Estradiol transdermal spray - Acrux; Evamist

Latest Information Update: 02 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acrux
  • Developer Acrux; AMAG Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Vasomotor symptoms

Most Recent Events

  • 01 Dec 2016 Alvogen Pine Brook completes a phase III trial in Atrophic vaginitis in USA (NCT02995694)
  • 01 Apr 2016 Alvogen Pine Brook initiates enrolment in a phase III trial in Atrophic vaginitis in USA (NCT02995694)
  • 12 Nov 2014 Lumara Health has been acquired by AMAG Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top